JP2025506322A - 放射性核種錯体の大規模合成のための方法 - Google Patents

放射性核種錯体の大規模合成のための方法 Download PDF

Info

Publication number
JP2025506322A
JP2025506322A JP2024532528A JP2024532528A JP2025506322A JP 2025506322 A JP2025506322 A JP 2025506322A JP 2024532528 A JP2024532528 A JP 2024532528A JP 2024532528 A JP2024532528 A JP 2024532528A JP 2025506322 A JP2025506322 A JP 2025506322A
Authority
JP
Japan
Prior art keywords
solution
concentration
salt
mother solution
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506322A5 (enExample
Inventor
バルバト，ドナート
ボ，ミケーレ
ロセット，マッティア
テデスコ，マッティア
ヴァレリオ，フェデリコ
Original Assignee
アドバンスド アクセラレーター アプリケーションズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドバンスド アクセラレーター アプリケーションズ filed Critical アドバンスド アクセラレーター アプリケーションズ
Publication of JP2025506322A publication Critical patent/JP2025506322A/ja
Publication of JP2025506322A5 publication Critical patent/JP2025506322A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024532528A 2022-02-04 2023-02-03 放射性核種錯体の大規模合成のための方法 Pending JP2025506322A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306822P 2022-02-04 2022-02-04
US63/306,822 2022-02-04
PCT/IB2023/050982 WO2023148680A1 (en) 2022-02-04 2023-02-03 Methods for large scale synthesis of radionuclide complexes

Publications (2)

Publication Number Publication Date
JP2025506322A true JP2025506322A (ja) 2025-03-11
JP2025506322A5 JP2025506322A5 (enExample) 2025-12-26

Family

ID=85221934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532528A Pending JP2025506322A (ja) 2022-02-04 2023-02-03 放射性核種錯体の大規模合成のための方法

Country Status (9)

Country Link
US (1) US20260053959A1 (enExample)
EP (1) EP4472678A1 (enExample)
JP (1) JP2025506322A (enExample)
KR (1) KR20240146015A (enExample)
CN (1) CN118159303A (enExample)
CA (1) CA3235923A1 (enExample)
IL (1) IL313964A (enExample)
TW (1) TW202342112A (enExample)
WO (1) WO2023148680A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025029946A1 (en) * 2023-07-31 2025-02-06 Curium Us Llc [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
WO2025210599A2 (en) 2024-04-05 2025-10-09 Novartis Ag Combination therapies with dna damage response inhibitors and [ 177lu]lu-psma-617

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020021310A1 (en) * 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
LT4541381T (lt) * 2018-07-25 2026-03-25 Advanced Accelerator Applications S.A. Stabilūs, koncentruoti radionuklidų kompleksų tirpalai
EP3666451B1 (en) 2018-10-18 2021-03-03 Mitsubishi Electric Corporation Additive manufacturing machine and cooling method
CA3159337A1 (en) * 2018-10-31 2020-05-07 Advanced Accelerator Applications (Italy) Srl Methods for synthesis of radionuclide complex
SG11202113333SA (en) * 2019-06-14 2021-12-30 Edinburgh Molecular Imaging Ltd Compounds and methods of use

Also Published As

Publication number Publication date
CA3235923A1 (en) 2023-08-10
KR20240146015A (ko) 2024-10-07
EP4472678A1 (en) 2024-12-11
US20260053959A1 (en) 2026-02-26
IL313964A (en) 2024-08-01
WO2023148680A1 (en) 2023-08-10
TW202342112A (zh) 2023-11-01
CN118159303A (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
KR102767449B1 (ko) 방사성핵종 착물의 합성 방법
US12605447B2 (en) Stable formulations for radionuclide complexes
WO2020021310A1 (en) Stable, concentrated radionuclide complex solutions
JP7436512B2 (ja) 腎保護物質としてのパラアミノ馬尿酸（ｐａｈ）
US20210379212A1 (en) Stable, concentrated radionuclide complex solutions
JP2025506322A (ja) 放射性核種錯体の大規模合成のための方法
US20090155167A1 (en) Automated method
JP2025506001A5 (enExample)
RU2826739C2 (ru) Способы синтеза радионуклидного комплекса
RU2859685C2 (ru) Фармацевтическая композиция в форме раствора для внутривенного введения на основе металлокомплексов бета-эмиттеров: лютеций-177 или тербий-161 и агонистов соматостатиновых рецепторов: DOTA-TATE, DOTA-TOC, DOTA-NOC
WO2023164769A1 (en) Radiopharmaceutical and methods
van Eerd-Vismale et al. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251217